Format

Send to

Choose Destination
Oncotarget. 2010 Jul;1(3):168-74.

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

Author information

1
Department of Genetics, the University of Texas, M D Anderson Cancer Center, Houston, TX, USA.

Abstract

A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.

PMID:
21301048
PMCID:
PMC3157715
DOI:
10.18632/oncotarget.100712
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center